, and the effect of such interventions may be observable only after a decade. In the meantime, a bet ter understanding of the biological mechanisms under pinning this link might identify intermediary biomarkers of cancer risk and potential new preventive strategies. As the prevalence of overweight and obesity have inexora bly risen in developed and lessdeveloped countries in the past three decades, addressing the prevention of can cers attributed to excess adiposity is a globally important health problem 4 . In their seminal review in 2004, Calle and Kaaks 5 pro posed three 'hormonal' candidate mechanisms for the adiposity-cancer link: altered sex hormone metabolism, increased insulin levels and bioavailability of insulinlike growth factor I (IGF1), and adipokine pathophysiology. In the intervening years, the mechanism of adipokine pathophysiology has been expanded to include systemic (subclinical) inflammation. In this Review, we first pro vide an update on the epidemiological evidence on the associations between BMI and cancer risk, in an attempt to identify clues about different prevailing mechanisms for the increased risk of cancer according to different sites, gender, geographical populations, histological subtypes and molecular phenotypes. Second, we summarize the aforementioned candidate mechanisms and highlight sev eral shortfalls to these hypotheses. Third, we summarize the effect of weightlosing interventions on intermediary biomarkers from the above candidate systems. Fourth, we describe in more detail how epidemiology has informed the emerging importance of body fat distribution, par ticularly local ectopic fat, as a para crine mechanism for cancer development. Finally, we turn to future directions and examine how new technologies may better define body fat compartments at population levels. As a prelude, TABLE 1 summarizes current methods for measuring body adiposity and body fat distribution 6 . BMI and cancer risk Specificity of BMI-cancer associations. The sec ond report of the World Cancer Research Fund and American Institute for Cancer Research (WCRF/AICR) global perspective 2 in 2007 concluded that there was "convincing" evidence that body fatness, generally measured by calculating BMI, was associated with an increased risk of oesophageal adenocarcinoma and can cers of the pancreas, colorectum, postmenopausal breast, endometrium and kidney, and evidence of a "probable" association of body fatness with increased risk of gall bladder cancer. Simultaneously, we reported a systematic review and dose-response metaanalysis of prospective cohort studies (221 datasets including 281,137 incident cancer diagnoses) quantifying incident relative risk for increases of 20 cancer types, expressed per 5 kg per m 2 increase in BMI 1 . By using a standardized approach across a large number of cancer types, our analysis dem onstrated that BMI-cancer associations are: sex specific (for example, the risk of developing colon cancer is more pronounced for men than for women); site specific (for example, the risk of developing colon cancer is more pronounced than that of rectal cancer); histology spe cific (for example, an association exists for oesophageal adenocarcinoma but not for oesophageal squamous cell Body mass index (BMI) . An anthropometric measure of body adiposity defined as the body mass (in kilograms) divided by the square of the body height (in metres).
Sex hormone
A family of hormones that share a basic chemical (steroidal) structure. These hormones include androgens, oestrogens and progesterone, and they have important effects on sexual development and reproductive functions.
Bioavailability
The proportion of a substance that can be used physiologically by target tissues.
Cohort studies
Studies in which a group of individuals is investigated prospectively over time. This is the preferred epidemiological study method for evaluating anthropometric measures and cancer risk.
Relative risk
The risk of cancer (or other disease) in a group of exposed persons divided by the risk in a group of unexposed persons. Relative risk is a commonly used measure of association in epidemiological studies.
Effect modification
Also known as effect interaction. When the association of an exposure with the risk of disease differs in the presence of another exposure.
carcinoma (SCC)); and broadly consistent across geo graphical populations, with some notable exceptions of specificity (for example, there is an increased risk of premenopausal breast cancer in AsiaPacific populations but not North American and European populations). This analysis also demonstrated that BMI-cancer risk associations exist for a wider range of malignancies than previously thought, including thyroid cancer, malignant melanoma in men, multiple myeloma, leukaemia and nonHodgkin lymphoma.
Subsequent updated dose-response metaanalyses, using data mainly from prospective studies, reported positive associations between BMI and subsequent increased risk of pancreatic cancer (after taking account of the effect modification of smoking, discussed below) 7 , ovarian cancer (after taking account of the effect modi fication of hormone replacement therapy (HRT), dis cussed below) 8, 9 and Hodgkin lymphoma 10 . Singlestudy reports indicate modest associations between BMI and bladder cancer 11 and increased BMI in early adulthood and glioma risk 12 ; a metaanalysis showed no associations between BMI and testicular cancer 13 .
A recently published large analysis of the UK Clinical Practice Research Dataset, which includes 5.24 million individuals with 166,955 new cancers (of 22 types), corrob orated many of the above findings for many can cer types and with similar risk estimates 14 . Importantly, as this was a 'same population' analysis, the authors were able to observe withinpopulation heterogeneity in the effects of BMI on the risk of developing multiple cancer types, and they speculate that "different mechanisms are associated with different cancer sites and different patient subgroups".
When the relationship between BMI and risk of all prostate cancer is examined, risk estimates generally show no association 1 , or even show an inverse associa tion 14 , and there is often considerable betweenstudy heterogeneity . Previously, there had been debate about whether such heterogeneity reflects effect modification due to different levels of prostatespecific antigen (PSA; also known as KLK3) screening across different popula tions and for different periods of time 15 . In recent years, the relationship between BMI (and indeed, other anthropometric measures) and prostate cancer risk has become clearer. Specifically, there is considerable evidence from prospective cohorts demonstrating that increased BMI is associated with increased risk of advancedstage pros tate cancer 16, 17 . 18 . Adult weight gain is also associated with incident risk of cancer. A recently reported dose-response meta analysis of 50 prospective studies demonstrated that patterns of association between adult weight gain and cancer incidence mirror those for BMI and cancer 19 . As adult weight gain correlates with lateradulthood BMI (cohort baseline), and this is the BMI value most com monly determined in epidemiological studies assessing BMI-cancer associations, it is unclear whether adult weight gain is more informative for assessing cancer risk than BMI per se.
Effect modifications of BMI-cancer associations.
There are three cancer types for which the associations between BMI and cancer risk are consistently inverse: 
Anthropometric measures
Measurements of the size or proportions of the human body: for example, weight, height and waist circumference.
Summary risk estimates
The weighted summations of collections of study-level risks derived from meta-analyses of studies. These estimates are typically reported as risk or point estimates with 95% confidence intervals.
Confounding
The association or lack of association with an exposure that is actually due to another factor that determines the occurrence of a disease but that is also associated with the exposure.
Anovulation
A menstrual cycle that is not accompanied by the discharge of an egg from the ovary.
lung cancer, oesophageal SCC, and head and neck can cers. It is now established that cigarette smoking is an effect modifier of the associations between BMI and lung cancer 14, 20 and between BMI and oesophageal SCC 21 , and it is the most likely explanation for the posi tive association between leanness and increased risk of head and neck cancers 22, 23 . Given that mean BMI val ues are generally lower in ever smokers than in never smokers 24 , and that smoking is a strong risk factor for lung cancer and oesophageal SCC, the observed inverse associations probably reflect confounding or, in adjusted analy ses, residual confounding by smoking 25 . In the absence of smoking, associations between BMI and these cancers are probably close to null. Smoking also affects the association between BMI and pancreatic cancer 7 , but in this case there is a positive association between BMI and cancer risk in the absence of smoking, whereas there is no association in the presence of smoking.
An additional effect modifier of BMI-cancer risk associations is HRT. The risk estimates between BMI and cancer stratified by HRT use are shown in TABLE 3 for postmenopausal breast 26 , endometrial 27 and ovar ian 8 cancers. In all three cancer types, associations between BMI and cancer risk are strongest for never HRT users, and associations are attenuated among ever users. The type of HRT (oestrogen alone versus com bined oestrogen and progesterone) does not seem to be important. This suggests that endogenous sex hor mones are on the causal pathway between adiposity and occurrence of these cancers; when these pathways are diluted in the relatively elevated doses of exogenous sex hormones in HRT, BMI-cancer risk associations are less pronounced.
BMI and premenopausal breast cancer. The case of adi posity and premenopausal breast cancer risk deserves specific mention. Data from prospective studies con sistently report an inverse association between BMI and premenopausal breast cancer risk (approximately 10% reduced risk per 5 kg per m 2 ), in North American and European populations 1, 28 . Conventionally, this is explained by ovarianderived androgen excess and chronic anovulation, and an associated reduction of lutealphase progesterone production (proges terone deficiency). This hypothesis is supported by two analyses of the serum levels of various sex hormones in large prospective cohorts 29, 30 , which reported that excess androgen levels were associated with increased premenopausal breast cancer risk.
However, it is incorrect to assume that this asso ciation presents a 'protective' effect of female sex hormones. Alternative explanations, including methodological reasons, may exist. Thus, by con trast, among women from AsiaPacific populations, increased BMI is associated with an increased risk of premenopausal breast cancer (approximately 15% increased risk per 5 kg per m 2 ) 1, 31 . Additionally, among women from North American and European popula tions, associations between anthropometric measures of abdominal fatness (such as waist circumference (WC) and waist/hip ratio (WHR)) and premeno pausal breast cancer risk are generally null or modestly positive [32] [33] [34] . Collectively, these observations suggest that, in some populations, BMI might be too crude a measure of body fatness to accurately quantify the relationship between adiposity and premenopausal breast cancer. Another alternative explanation is that height squared in the BMI formula inadequately adjusts for height in women 35 (height is an independent risk factor for breast cancer 36 ). For example, short, obese young women may have a low risk of premenopausal breast cancer owing to their low height, even though they have high BMI 37 .
Associations with molecular phenotype. Increasingly, tumours are classified based on their molecular profile. Such classifications afford opportunities to enhance the exploration of exposure-disease associations and to infer specific causal pathways. Large epidemiological studies are now exploring these relationships and their interaction with BMI (summarized in TABLE 4).
For breast cancer, a relatively simple molecular classi fication is based on immunohistochemical expression of oestrogen receptor (ER) and progesterone receptor (PR). The evidence linking BMI and ER-PR status with breast cancer risk has been mounting and was initially sum marized in a metaanalysis published in 2009 (9 cohorts; 22 casecontrol studies) 38 . Since then, additional findings from several large cohorts have been published [39] [40] [41] [42] [43] [44] , as has a pooled analysis from the Breast Cancer Association Consortium 45 . ER + PR + tumours account for approxi mately 60% of premenopausal breast cancers. For these tumours, the BMI-cancer risk associations broadly mir ror those seen in studies in which there are no molecular classifications: namely, an approximate 10% risk reduction for premenopausal breast cancer and 33% risk increase for postmenopausal breast cancer per 5 kg per m 2 BMI increment 38 . For ER − PR − breast cancer risk, results have been mixed in postmenopausal women, but most cohort studies find no association 39, [46] [47] [48] [49] or a reduced risk with increased BMI 43 . However, two recent studies found posi tive associations between increasing BMI and the inci dence of triplenegative tumours (that is, tumours that are ER − PR − and do not express human epidermal growth factor receptor 2 (HER2; also known as ERBB2)) in all study participants 44 and in a subgroup of never HRT users 42 . Among premenopausal women, there may also be positive associations between abdominal adiposity and triplenegative breast cancer 41 . These observations suggest that, in terms of adipositydriven mechanisms of tumour development, ER + and ER − tumour types may share com mon pathways. It has been hypothesized that a large pro portion of ER − tumours arise from oestrogenresponsive precursor tumours or cells and that oestrogen sensitivity is lost during tumour development 50 . In addition, mammary stem cells are known to be responsive to sex hormones despite not having detectable expression of ER or PR 51 . Endometrial cancers have long been subclassified into Bokhman's type 1 endometrioid tumours (≥70%) and type 2 (other histology) tumours 52 ; type 1 tumours are oestrogendriven and conventionally associated with adipositydriven pathways. The exact definitions of type 2 histological subtypes vary across the litera ture, but despite this we and others, through nonlinear piecewise metaanalysis 27 and consortium analyses 53 , respectively, have shown that BMI-cancer risk associa tions are greater for type 1 than for type 2 endometrial carcinomas.
Histological classification of ovarian cancers is com plex and not standardized across epidemiological stud ies. Nonetheless, differential associations exist between subtypes of ovarian cancer and BMI. A pooled analysis of studies participating in the Ovarian Cancer Association Consortium (15 casecontrol studies) convincingly showed that there are no associations between BMI and the most common type of ovarian cancer, serous ovarian carcinoma (which accounts for 66% of ovarian cancer cases), whereas positive associations exist with less common histological types, such as mucinous ovarian carcinomas and endometrioid carcinomas of the ovary 54 . These findings are consistent with cohort studies in the Collaborative Group on Epidemiological Studies of Ovarian Cancer (17 cohorts) 8 . There are at least two main classes of colorectal cancer: those exhibiting microsatellite stability (MSS; 85% of cases) and those with microsatellite instability (MSI; 15% of cases). Data from three casecontrol studies suggest that positive associations between BMI and colon cancer are restricted to MSS tumours [55] [56] [57] . By contrast, pooled data from The Netherlands Cohort Study and Melbourne 
Attributable risk
In epidemiology, this is the difference in the rate of a condition between an exposed population and an unexposed population.
Peripheral adipose tissue
Fat stores other than intra-abdominal fat (mainly subcutaneous fat).
Collaborative Cohort Study found no effect modification for colorectal cancer by MSI status and BRAF mutation status 58 . Differences may reflect lack of a universal defi nition for CpG island methylator phenotype (CIMP), which is a key determinant of microsatellite status. Additionally, casecontrol studies in colon cancer indi cate that tumour expression of fatty acid synthase (FASN; a regulator of fatty acidderived energy metabolism) and βcatenin (a mediator of the WNT pathway encoded by CTNNB1) may modify the effect of BMI on colon cancer risk. Thus, the association between BMI and increased colon cancer risk is limited to colon tumours expressing FASN 59 or those not expressing βcatenin 60 . Taken together, and assuming that these associa tions are causal (discussed below), a recent study using the GLOBOCAN 2012 data estimated attributable risk and numbers of new cancer cases attributable to high BMI 4 . These analyses took account of the effect modi fications of countrylevel smoking prevalence and HRT use. The summary estimate reported that 3.6% of all new cancers in adults aged 30 years and older (exclud ing nonmelanoma skin cancer) in 2012, or 12.8% of highBMI associated cancers, are attributable to high BMI 4 . These figures are equivalent to an estimated 481,000 new cancers worldwide that might have been caused by high BMI.
Mechanisms that explain adiposity-cancer links need to account for the specificities of these asso ciations for gender, site, histological and molecular subtypes; using observations such as effect modification may also help researchers to narrow down the specific mechanisms underlying these associations in certain cancer types.
Current hypotheses of biological mechanisms
Three hormonal mechanisms have been proposed to explain links between adiposity and increased cancer risk (FIG. 1) : sex hormone metabolism, insu lin and IGF signalling, and adipokine pathophysi ology 5, [61] [62] [63] . Subclinical inflammation has also emerged as important and is intimately connected to the adipokine system. Sex hormone hypothesis. This hypothesis applies pre dominantly, but not exclusively, to postmenopausal breast, endometrial and ovarian cancers. In the setting of excess adiposity, increased risk in these cancers is explained by the higher rates of conversion of andro genic precursors to oestradiol through increased aro matase enzyme activity in peripheral adipose tissue -a process known as aromatization 64 . For breast cancer, there is abundant experimental evidence from in vitro and animal models that oestrogens are mitogenic and, indeed, mutagenic: they induce direct or indirect freeradicalmediated DNA damage, genetic instabil ity and mutations in cells in normal and neoplastic mammary tissues 65 . Altered concentrations of circu lating oestrogen related hormones are linked to breast cancer risk. Specifically, the Endogenous Hormones and Breast Cancer Collaborative Group (EHBCCG) 66 and the European Prospective Investigation into Cancer and Nutrition (EPIC) study 67 reported similar find ings: postmenopausal breast cancer risk is increased (typically twofold for upper versus lowest quintiles) among women with higher concentrations of circulat ing sex hormones including dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS), Δ4androstenedione, testosterone, oestrone and total oestradiol, and decreased concentrations of sex hormonebinding globulin (SHBG). In the EHBCCG analysis, the association of BMI with postmenopausal breast cancer risk was almost entirely explained by the increase in oestradiol levels with higher BMI 66 . Adiposity is negatively correlated with testosterone concentrations in men 68 but positively correlated in women 66 . The EHCCBG 65 and EPIC 67 analyses demon strated that elevated blood concentrations of androgens are associated with increased risk of breast cancer in both premenopausal and postmenopausal women. Thus, androgens may be potential candidates linking obesity and breast cancer. However, the experimental evidence is conflicting: the conventional wisdom is that androgens inhibit normal breast growth but, in animal and cultured cell experiments, androgens may have either inhibitory or stimulatory effects (reviewed elsewhere 64 ). For endometrial cancer, increased oestradiol lev els not only increase endometrial cell proliferation and inhibit apoptosis (attributes that favour tumori genesis) but also stimulate the local synthesis of IGF1 in endometrial tissue 5 . Indeed, the proliferative actions of oestradiol on endometrial tissue are mainly medi ated by an increase in the local production (mostly in uterine tissue) of IGF1. Progesterone diminishes oes trogenic action in the endometrium by stimulating oestradiol metabolism and inducing the synthesis of IGFbinding protein 1 (IGFBP1), which inhibits IGF1 (REF. 69 ). Endometrial cancer offers an example in which more than one biological mechanism might link obesity with increased cancer risk. Similarly to studies for breast cancer risk, epidemiological studies support an unop posed oestrogen hypothesis for endometrial cancer, but ovarian hyperandrogenism (and concomitantly reduced progesterone levels) may also play a part 69 . Androgens are important in the maturation of the prostate gland, but prospective studies assessing the associations between circulating sex hormone con centrations and prostate cancer risk have reported incon sistent findings. In men, compared with normal weight, obesity is associated with lower mean concentrations of serum testosterone, so how can sex hormones explain the observed links between obesity and advancedstage prostate cancer? It is speculated that a lowtestosterone environment (paradoxically) favours the development of a lessdifferentiated, aggressive cancer phenotype 70 , although the supporting evidence is currently limited and indirect. The Prostate Cancer Prevention Trial 71 reported that finasteride, which lowers dihydrotestos terone levels, decreased risk of welldifferentiated pros tate cancer while simultaneously being associated with an increased risk of highgrade prostate cancer (Gleason grade ≥7). Two prospective studies 72, 73 reported that low concentrations of testosterone in serum were associated with a higher risk of poorly differentiated prostate can cer; these findings need corroboration and adjustment for BMI.
There are limitations to the sex hormone hypothesis. First, circulating sex hormone levels change cyclically in premenopausal women, making it challenging to meas ure a 'steady state' of risk or risk modification. Second, the focus is on endocrine effects, but it is increasingly appreciated that paracrine mechanisms are key to 
Reporting bias
A scenario in which investigators fail to report outcomes in studies, often because these associations are not significant.
the link between adiposity and cancer risk (discussed below), particularly for breast cancer 61, [74] [75] [76] . 77 , but whether endogenous physiological range oestrogenrelated hormones offer some degree of attenuation of the BMI-cancer association in women is speculative.
Insulin resistance and IGFs. Circulating insulin levels positively correlate with increasing BMI, and many obese individuals are insulin resistant. Two decades ago, McKeownEyssen 78 and Giovannucci 79 suggested that hyperinsulinaemia may contribute to cancer develop ment through two pathways: direct growthpromoting signalling of elevated levels of insulin, and indirectly through what has come to be known as the insulin-IGF hypothesis. The latter postulates that prolonged hyper insulinaemia reduces production of IGFBP1 and IGFBP2 (which normally bind IGF1 and inhibit its action), with resultant increases in the levels of free or bioactive IGF1 and concomitant changes in the cellular environment that favour tumour development. Activation of the insulin receptor (IR) and IGF1 receptor (IGF1R) trig gers cancerrelevant intracellular signalling cascades including those required for mitogenesis, antiapoptosis, angiogenesis and tumourassociated lymphangiogenesis, which favour tumour development and spread 80 . In parallel, a large volume of epidemiological stud ies have examined the relationships between circulat ing total IGF1 and cancer risk. Our metaanalyses 81, 82 of these studies support relationships between total IGF1 levels and the risk of developing prostate, colorectal, pre menopausal breast and postmenopausal breast cancer. Initial studies reported inverse associations between circulating levels of IGFBP3 (the signalling of which is thought to have antiapoptotic effects) and cancer risk, but subsequent epidemiological studies did not replicate these findings 82 .
There are several shortfalls to the insulin-IGF hypothesis. Considering the insulin component: first, in epidemiological studies, the measurement of serum insulin levels is highly dependent on the state and dura tion of fasting, assay characteristics and genetic factors, and, accordingly, surrogates of insulin secretion (for example, Cpeptide) or of insulin resistance (for example, homeostasis model assessment) are often used. It is now recognized that these surrogates are poor indicators of individual insulin resistance 83 . Determination of plasma glucose levels 2 hours after an oral glucose load is an alternative surrogate of insulin resistance, but currently the resourceheavy assessment of this exposure (as a con tinuous measure) with cancer has been limited to the end point of cancerassociated mortality in the DECODE col laboration 84 . Second, although there is a large volume of animal model data supporting the link between supra physiological levels of insulin and tumour promotion 85 , these insulin levels are not applicable in humans and the direct tumourdevelopment effect attributable to insulin is probably very modest. Third, the biology of insulin and IGF1R systems is complex. Hybrid receptors of IR and IGF1R exist that bind insulin and IGF1, and IR may exist as isoform A (IRA) and isoform B (IRB). In many common adult malignancies, IR expression tends to be almost exclusively IRA. IGF1 has stronger binding affinity for IRA compared with IRB and, on theoretical grounds, much of the direct tumourpromoting action of IR may be through IGF1, rather than through insulin binding. Finally, if insulin signalling is invoked as a candi date mechanism to explain adiposity and cancer risk, one would expect that exogenously administered insulin in patients with diabetes might be associated with increased cancer risk. Although epidemiological studies raised this concern in the late 2000s, it is now appreciated that these associations spuriously resulted from methodo logical limitations in the study analyses 86 , and they failed to emerge in a secondary analysis of the large ORIGIN trial of the longacting insulin analogue glargine versus standard of care 87 . Considering the IGF1 component: first, in mice, total levels of IGF1 increase with increasing fatness across the range of weights; however, this is not true for humans, in whom total levels of IGF1 increase only to a BMI of approximately 27 kg per m 2 , thereafter declining with increasing weight 88 . Second, in the human circulation, IGF1 is heavily bound to various IGFBPs. The struc tural relationship of IGF1 to IGFBPs differs in tissue, and there is no direct evidence that circulating IGF1 levels correlate with cellular downstream pathways at a tissue level. Third, a review of epidemiological studies has raised concerns that there may be reporting bias for studies describing significant associations between either insulin or IGF1 and cancer risk 89 . Finally, in overweight individuals who intentionally lose weight, total and free IGF1 concentrations tend to increase (discussed below) 90 .
Adipokine pathophysiology and systemic inflammation. Polypeptide hormones derived from adipocytes are known as adipokines 91 . There are more than 50 fifty different types of adipokines; leptin and adiponectin are the types most studied in the context of cancer risk. Adipokines are associated with the inflammatory sys tem; for example, leptin is a potent inflammatory agent, whereas adiponectin has potent antiinflammatory activity.
Systemic leptin concentrations are proportional to the amount of body fat, as insulin induces leptin gene expression to signal suppression of appetite. Mean levels Visceral adipose tissue (VAT). Adipose tissue arising in the abdominal cavitynamely, the omentum, mesenteric and retro-peritoneal fat stores -but excluding within-viscera fat, such as intrahepatic and intrapancreatic fat.
Biomarkers
Characteristics that are objectively measured and evaluated as indicators of normal biological processes, pathogenic processes or pharmacological responses to a therapeutic intervention.
of insulin are higher in women than in men 92 . Leptin is potentially relevant for cancer development: it has pleio tropic effects, it is mitogenic (notably, in breast, colon and prostate cancer cell lines), it is antiapoptotic, it mediates immune suppression, and it is proangiogenic by itself and in synergy with vascular endothelial growth factor (VEGF) 93, 94 . The leptin receptor occurs as at least four splice variants, but only the long form (LRb) has an intracellular domain of sufficient length to provide full signaltransducing capabilities 95 . LRb activates PI3K, MAPK and signal transducer and activator of transcrip tion (STAT) signalling, which are critical pathways involved in cell survival, proliferation and differentia tion 62 . Despite this repertoire of mechanisms, epidemi ological studies assessing associations between serum leptin concentrations and cancer risk have reported inconsistent findings (reviewed elsewhere 96, 97 ). Adiponectin is the most abundant adipokine, secreted mainly from visceral adipose tissue (VAT). Unlike leptin, it is produced only by mature adipocytes. Serum adiponectin levels are negatively correlated with BMI and, in turn, insulin and oestrogens may suppress adi ponectin secretion 98 . After adjustment for BMI, serum concentrations of adiponectin are higher in women than in men, and higher in postmenopausal than in premenopausal women 99 . Of importance to tumour development, adiponectin may have indirect effects, sensitizing cells to insulin or through anti inflammatory actions. It may also have direct effects: adiponectin sequesters growth factors at the prereceptor level or by binding to adiponectin receptor 1 (ADIPOR1) and ADIPOR2, activating AMPactivated protein kinase (AMPK) while inhibiting ERK1 and ERK2, PI3K-AKT, WNT-βcatenin, nuclear factorκB (NFκB), and Janus kinase 2 (JAK2)-STAT3 signalling. Collectively, these effects result in reduced fatty acid and protein synthe sis, decreased cellular growth, proliferation and DNA mutagenesis and increased cell cycle arrest and apopto sis, thus negatively influencing carcinogenesis (reviewed elsewhere 100 ). Against this biological background, a com prehensive review 100 of the epidemiological data shows broadly consistent inverse associations between circu lating adiponectin concentrations and risk of obesity associated cancers, including endometrial, breast, advanced prostate, colorectal, renal, and pancreatic (mainly in never smokers) cancers but not lung cancer (see Supplementary information S1 (table)).
Adiposity is associated with a state of chronic (sub clinical) inflammation. As adipose tissue expands, the levels of Creactive protein (CRP), tumour necro sis factor (TNF), interleukin1β (IL1β), IL6 and IL18 increase [101] [102] [103] . An early epidemiological study showed an association of CRP levels with colorectal cancer 104 , but a subsequent metaanalysis of eight pro spective studies reported only modest correlations 105 . Later studies showed either positive associations 106, 107 or no relationship 108 . Here again, there are several caveats and short falls. First, the molecular assembly of adiponectin is complex. There are three major oligomeric forms of adiponectin: a lowmolecularweight (LMW) trimer, a middlemolecularweight (MMW) hexamer and a highmolecularweight (HMW) multimer. LMW oli gomers are the predominant form in the circulation, whereas the majority of intracellular adiponectin con sists of HMW multimers. The ratio of HMW to LMW is critical to insulin sensitivity. The biological effects of adiponectin depend on not only relative circulating concentrations but also its form and the tissuespecific expression of its receptor subtypes (ADIPOR1 and ADIPOR2). Both adiponectin receptors may exist in tumour cells 109 , but more studies are needed to char acterize these subtypes and their functions. Second, studies in fatless AZip/F1 mice, which have unde tectable adipokine levels in the circulation but display accelerated tumour formation, suggest that adipose tis sue is not essential for tumour development 110 . Third, a review of epidemiological studies of biomarkers and subsequent cancer risk has raised concerns about biased reporting in studies of inflammation biomark ers 89 . Circulating levels of adipokines and inflamma tory markers fluctuate considerably in the presence of chronic diseases, differing diets, medications and differing levels of physical activity 62, 111 . Against these background inconsistencies, there is a continuing need to refine existing hypothesized mechanisms for the link between adiposity and cancer as well as to find additional mechanisms that explain the specificity of the epidemiological observations.
Weight loss and cancer-relevant biomarkers
Weightlosing interventions may affect intermediary biomarkers. Thus, observations from weightlosing studies could implicate some of the above hypotheses in obesityassociated cancer risk. Byers and Sedjo 112 published a comprehensive review of studies evaluat ing changes in cancerrelevant risk biomarkers, namely: oestrogens, SHBG, IGF1, IGFBPs and the inflamma tory markers CRP, IL6 and TNF. Their findings were as follows. First, oestrogen levels drop and SHBG levels increase coincident with intentional weight loss, with about a onethird reduction in free oestradiol to be expected from a 10% weight loss. Second, CRP levels drop by about onethird after weight loss. Third, reduc tions in TNF and IL6 levels are consistently seen but are of a smaller magnitude. Fourth, changes in levels of IGF1 and IGFBPs are small and may be in either direction.
It is possible that the observed inconsistencies and small effects reflect measurement errors (in the assays) or chance findings in small sample sizes. An alterna tive and more plausible explanation is that the lack of substantial change in some intermediary biomarkers (for example, IGF1) in a cancerprotective direction, in the face of substantial weight reduction, argues against that biomarker being a key intermediary in obesity associated carcinogenesis. One recent large randomized trial of dietary and exercise interventions reported no significant changes in IGF1 and IGFBP3, despite sub stantial reductions in body weight in the experimental groups 113 , leading the authors to remark that: "modi fied IGF1 bioavailability is unlikely to be a mechanism through which caloric restriction reduces cancer risk". Nature Reviews | Cancer Body fat distributions and cancer risk BMI does not fully capture the complex biology of adiposity. Excess body fat is a heterogeneous condi tion in which individuals with similar BMIs may have distinct metabolic and cardiovascular disease risk 114 . Variation in body fat distribution provides a poten tial explanation for some of the risk differential that persists after accounting for BMI and standard dis ease risk factors 115 . Increasingly, it is recognized that a proportion of overweight or obese individuals might not be at an increased risk for metabolic complica tions of obesity and have a phenotype referred to as metabolically healthy obesity (MHO), which contrasts with the metabolically unhealthy obesity (MUO) phe notype 116 . This new classification is driving treatment algorithms in individuals at risk of cardiovascular dis ease and type 2 diabetes and may have an application in cancer epidemiology. For example, results from the Framingham Heart Study 117 suggest that cancer risk may be lower among MHO older adults than among MUO individuals.
Classification of types of ectopic fat. Body fat distribu tion differs between MHO and MUO individuals: for example, MHO individuals have less local ectopic fat than MUO individuals. The clinical importance of local ectopic adipose tissue depots, which surround organs and blood vessels or are located within organs, is now well recognized, as these depots are key risk factors for cardiovascular disease 118 . Thus, understanding and classifying ectopic fat depots (systemic and local) is important (FIG. 2) .
Sites with predominantly systemic effects include VAT and intramuscular fat: these have a wellestablished role in the development of cardiovascular disease 119 . With the development of obesity, VAT is infiltrated . Monocyte chemoattractant protein 1 (MCP1; also known as CCL2) is a key molecule that mediates this macrophage infiltration 138 . Additionally, the number of regulatory T cells decreases while the number of CD8 + T cells increases, promoting further macrophage recruitment. CLSs, crown-like structures; ECM, extracellular matrix; IL-6, interleukin-6; TAMs, tumour-associated macrophages; TNF, tumour necrosis factor; VAT, visceral adipose tissue.
Central adiposity
The storage of adipose tissue preferentially in adipocytes within the trunk rather than the extremities.
Steatosis
The accumulation of intracellular fats, mainly triglycerides. Used typically to describe fat deposition within the liver (hepatic steatosis) but may equally apply to fat accumulation in other organs.
by macrophages, and there is dysregulation of various fat secreting factors that are important in the development of a subclinical systemic inflammation state and insu lin resistance 120 . Although volumes of intrahepatic and intramuscular fats are much smaller than those of VAT, they may exert 'overspill' effects and contribute to sys temic metabolic disease, and they are key determinants of insulin resistance 121 . In contrast to ectopic fat with predominantly sys temic effects, local fat depots surrounding the heart, blood vessels and kidneys correlate more strongly with metabolic disease states in the respective organs 118 . For example, pericardial fat has a stronger correlation than VAT has with coronary artery disease. This paradigm is now extending to cancer biology. For example, breast adipose tissue is an established ectopic fat depot with potential local effects on cancer development 61 .
Systemic ectopic fat (central adiposity) and cancer risk.
WC was one of the earliest means of quantifying body fat distribution, as an approximation of central adiposity. With ageing, individuals lose lean body mass and gain weight as VAT. Metabolically active visceral fat releases substantial amounts of growth factors, inflammatory markers, free fatty acids (contributing to insulin resistance) 122 , locally produced oestrogen and adipokines, which might con tribute to the development of diseases, including can cer. In epidemiological studies, individuals with larger amounts of visceral fat, as identified by their larger WC, have a higher risk of cardiovascular disease and type 2 dia betes than individuals with smaller amounts of VAT. In turn, anthropometric measures of central adiposity (such as WC and WHR) correlate more strongly than BMI with visceral fat, and they are thought by some investigators to be better indicators of cancer risk 123 . Early studies supported the above hypothesis. For example, for colorectal cancer, in prospective studies in which both BMI and WC (or WHR) were meas ured and risk estimates determined for the develop ment of colorectal cancer, risk seemed to be greater for WC in both genders 124 , or in women 125 . Furthermore, adjustment for BMI did not seem to attenuate associa tions 124, 125 . Similarly, for postmenopausal breast cancer, early results from the Iowa Women Health Study 126 sug gested a statistically significant multiplicative interaction between age, BMI and WHR. However, in subsequent reports that specifically tested interactions between WC and BMI, in relation to colorectal 127, 128 and breast 40, 129, 130 cancer risk, statistically significant associations were not found. For more recently reported prospective studies evaluating the risk of developing other cancers in which both BMI and WC (or WHR) were measured and risk estimates determined, summary risk estimates from WCRF/AICR pooled analyses were broadly similar for equivalent increments of BMI and WC in cancers of the pancreas 131 , endometrium 132 and ovaries
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, and advanced prostate cancer 17 . Taken together, there is limited evidence that WC (or WHR) is a better predictor of cancer risk than BMI. Thus, as visceral adiposity is a key determinant of insu lin resistance, by extension, one would hypothesize that surrogates of central adiposity -for example, WC and WHR -are stronger predictors than BMI for cancer risk. However, the epidemiological evidence does not support this hypothesis. The current explanation is that WC is a poor approximation of central adiposity, as it captures both subcutaneous adipose tissue (SAT; which is typically nonectopic) and VAT (which is typically ectopic) (see Supplementary information S2 (table)), and there is a need to develop techniques to better quantify these separate fat depots 18 .
Local ectopic fat and cancer development. The theory of excess adipose tissue having a local toxic effect is supported by multiple lines of evidence from transla tional research 133 and epidemiology 134 . This theory is now increasingly relevant for the development of breast cancer and probably other types, such as hepatocellular carcinoma and pancreatic cancer 18 . The amount of fat at these sites is proportional to the total body fat mass 18, 135 , but these fat depots retain residual independence and thus might be more relevant than total body adiposity to local tumour development. In breast cancer, the cel lular and metabolic makeup of the local adipose tissue is additionally important for tumour progression and metastasis (reviewed elsewhere 61, 136, 137 ). A hallmark of local ectopic fat deposition is local inflammation 103, 138 (FIG. 2) . The inflammatory media tors secreted by macrophages not only act locally, in a paracrine manner, but also may contribute to general systemic inflammation and promote an environment that favours tumour development. One clear example of this 'mirroring effect' is seen in the liver (and the hypothesized pathway to obesityassociated hepato cellular carcinoma). Hepatic steatosis is the intrahepatic accumulation of fats, commonly as a consequence of obesity, and may be a driver of insulin resistance and systemic inflammation 121, 139 . Nutritional insults induce reactive oxygen species, leading to the production of proinflammatory cytokines and the recruitment of immune cells to the liver, and eventually to nonalco holic fatty liver disease (NAFLD) 140 . NAFLD may pro gress to nonalcoholic steatohepatitis (NASH), a major risk factor for hepatocellular carcinoma, thus provid ing a possible link between obesity, insulin resistance, inflammation and the development of hepatocellular carcinoma (FIG. 3) . There are several animal models that support this paradigm 141, 142 . However, this process is not well understood, and the epidemiology is difficult to study 143 owing to the lack of a reliable, noninvasive tool to quantify NAFLD and to the presence of strong confounders (which have often not been measured in the epidemiological studies of this to date), such as viral infection and alcohol consumption 144 . Intrapancreatic fat, termed pancreatic steatosis, is an additional example of intraorgan fat deposition that increases with BMI 145 . Inflammation is a putative mechanism in the development of pancreatic cancer and a candidate obesitydriven pathway. In mice, excess fat intake leads to inflammation within the pancreas, lead ing to progression from normal pancreatic epithelium to pancreatic intraepithelial neoplasia, a precursor lesion Nature Reviews | Cancer of pancreatic cancer 146 . Here, again, an obesityinduced local inflammatory microenvironment seems to be important. Human data are just beginning to emerge to support this hypothesis 147 .
New mechanistic hypotheses
Intriguing new biological mechanisms are beginning to emerge that may be additional links between obesity and cancer risk.
Migrating adipose progenitor cells. The tumour stroma includes many different mesenchymal stromal cells (MSCs), which are important as progenitor cells for the formation of, for example, endothelial cells that are required for neovascularization. Intriguingly, MSCs are present in the circulation at low levels and may be recruited to tumour sites by pathological signals, such as hypoxia or inflammation (at least in mice) 148 . When recruited to the tumour, they become tumour stromal cells (also known as cancerassociated fibroblasts (CAFs)) and promote angiogenesis and drive tumour progression. Bone marrow was thought to be the main source of these circulating progenitor cells, but evidence indicates that they may arise from other sources, including white adipose tissue (WAT) 148 . In turn, WAT is expanded in obe sity, which may then be a link between the systemic fat volumes and local ectopic fat mechanisms.
The microbiome, obesity and cancer. Intestinal micro biota exist in a symbiotic relationship with their host, by metabolizing compounds that the host is unable to uti lize and controlling the balance of the immune responses in the host. However, the composition of the intesti nal microbiome varies with diet and pathophysio logical states, including obesity 149 . Recently developed omics technologies to capture microbial data provide new insights into the roles of intestinal micro organisms and their metabolism and, for example, suggest that the intes tinal microbiota contribute to colorectal carcino genesis (at least in mice) 150 , via the influence of their metabo lites. Importantly, it is now appreciated that gut micro bial metabolites 'spill over' into the host's circulation and are involved in the pathogenesis of cancers distant from the gastrointestinal tract 151 . This field is still new and links with cancer remain speculative but will require consideration in the future.
Future directions
More-detailed measures of body fat deposition. If local ectopic fat deposition 61 and organspecific fat deposi tion are indeed relevant for cancer development, the challenge is now to accurately quantify these using non invasive modalities in largeepidemiologicalscale stud ies, including, for example, magnetic resonance imaging and 1 H magnetic resonance spectroscopy (illustrative examples are provided in Supplementary information S2 (table) ). In the Framingham Heart Study 152 , more than 3,000 individuals already underwent ectopic fat quan tification using multidetector computed tomography scanning, with correlations to cardiovascular disease end points 152 . Largescale imaging is planned with the UK Biobank and the German Cohort study, with opportunities to correlate with cancer outcomes 18 .
Causal relationships and Mendelian randomization.
Up to this point, we have assumed that the associations between increased adiposity and cancer risk are caus ally related. Statistical associations between an exposure and an outcome in observational epidemiology can be spuriously produced by common causes of the exposure and the outcome, an effect known as confounding 153 . An example of this might be that increased adiposity is caused by other risk factors that cause cancer -such as increased energy intake, decreased physical activity or increased alcohol consumption -while obesity per se might have no causal effect on cancer risk (dis cussion expanded in Supplementary information S3 (table) using directed acyclic graphs (DAGs)). In prac tice, many epidemiological studies have adjusted for these confounders and shown that associations between adiposity and cancer risk remain, although residual unmeasured confounding may exist and adjustment for confounders might be only partial, as confounders might be measured with error.
Mendelian randomization may offer a solution to the problem of residual confounding, as it enables, under certain conditions, estimation of causal effects in obser vational studies using genetic variants as instrumental variables 154 . With a genetic variant taking the role of an instrumental variable (owing to the random assignment of alleles in gamete formation) one might, for example, estimate the average effect of the genetic variant on BMI difference and, in a second analysis, on disease risk. In turn, this would allow estimation of the increase in disease risk per unit increase in BMI. However, this would be pos sible only if the genetic variant (the instrumental variable) affects cancer risk only through its effect on BMI 155, 156 (BOX 1). More than 50 gene loci have been associated with the development of obesity through genomewide association studies but few Mendelian randomization studies have been undertaken to date 157, 158 . These focused on few gene loci and cancers, including polymorphisms in the CYP19A1 gene (which encodes aromatase) 159 , Figure 3 | Hypothesized steatosis-hepatocellular carcinoma pathway. In the absence of common hepatic insults, such as excess alcohol, accumulation of fat in the liver (nonalcoholic fatty liver disease (NAFLD)) is associated with chronic inflammation, known as nonalcoholic steatohepatitis (NASH). In some subpopulations, over time, NASD may progress either directly to hepatocellular carcinoma or indirectly through a cirrhosis state. ECM, extracellular matrix; IL-6, interleukin-6; TNF, tumour necrosis factor.
, and 28 obesityrelated SNPs in colorectal cancer 164 -but no consistent pattern has emerged.
Other modelling approaches. Several alternative mod elling approaches might be considered in this field to increase the power of causal inference for obesitycancer associations. Examples include structural equation modelling (which explores the extent to which the effect of an exposure on a disease risk acts through a putative mediator or mechanism: that is, it decom poses a total effect into an indirect (mediated) effect and a direct effect 165 ) using repeated measurements of, for example, BMI, and lifecourse analyses with BMI as a timevarying variable 117 . A further example is a holistic or factor analysis approach, as used in the EPIC cohort to clarify the role of obesityassociated biomarkers, with endometrial cancer as the cancer of interest 166 . This analysis 'clustered' related intermediary biomarkers into families and, for example, showed that members of the lipids were not associated with endometrial cancer risk.
In summary
We have identified four broad concepts. First, the epi demiological evidence shows specificity of associations between measures of adiposity and cancer risk. This indi cates that there is no one mechanism (or set of mecha nisms) that fits all. Second, the specificity of associations (demonstrated by the epidemiology) argues for a para digm shift towards local tissuespecific mechanistic rather than global systemic physiological explanations. Third, the weightreduction clinical trial data indicate that there is a range of sizes and directions of change in intermediary biomarkers, which in turn inform the mechanistic impor tance (or lack of importance) of a given proposed pathway. Fourth, the current epidemiological data fail to demon strate striking differences in cancer risk associations for BMI (as an approximation of total body adiposity) versus other anthropometric measures (as approximations of specific body compartments). The most likely explana tion is that current measures of body fat distribution (for example, WC) are too crude, and there is a continuing need for better characterization. At present, the most optimistic quantification modalities will come through largescale imaging projects. These epidemiological approaches will help to identify dominant mechanistic pathways and develop future cancerspecific targeted preventive strategies.
Note added in proof
Since this Review was accepted for publication, a large scale study has been published demonstrating the util ity of Mendelian randomization in the evaluation of the mechanisms linking obesity and cancer risk 167 , which relates to the discussion in BOX 2. From a consortium of studies from European ancestry populations, and using used SNPs associated with fasting insulin (18 variants), early insulin secretion (17 variants) and BMI (32 variants) as instrumental variables, this analysis (of 1287 cases and 8273 controls) provides evidence to support a causal asso ciation of higher insulin levels, independent of BMI, with endometrial cancer risk (cases, 1287: controls, 8273).
Box 1 | Mendelian randomization, obesity and cancer risk
Observational epidemiology suggests that obesity may be associated with increased risk of several cancer types, but such studies may have several problems, including confounding, reverse causation, selection bias and attenuation by measurement errors (regression dilution bias). Mendelian randomization may help to address these limitations.
Mendelian randomization studies use genetic variants as proxies of non-genetic risk factors to assess whether a risk factor is causally related to a disease. The approach exploits the independent randomized assortment of maternal and paternal alleles at the time of gamete formation to remove confounding and other biases. Instrumental variable analysis is used to obtain estimates for the association of the risk factor with the disease that can have a causal interpretation.
Genome-wide association studies (GWASs) reported in the past few years have revealed more than 50 gene loci associated with the development of obesity. Importantly, some loci predict a higher body mass index (BMI), and others are associated with central adiposity (as approximated by waist circumference (WC)).
Future analyses might make causal inferences through assessment of dispositional propensities (for example, tendency to get fatter), characterizing 'difficult to measure' exposures (for example, insulin resistance at a population level), and inter-generational influences.
